. 2014 Aug 20;32(37):4713-25.

doi: 10.1016/j.vaccine.2014.02.014. Epub 2014 Feb 28.

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013

Ian G Barr¹, Colin Russell², Terry G Besselaar³, Nancy J Cox⁴, Rod S Daniels⁵, Ruben Donis⁴, Othmar G Engelhardt⁶, Gary Grohmann⁷, Shigeyuki Itamura⁸, Anne Kelso⁹, John McCauley⁵, Takato Odagiri⁸, Stacey Schultz-Cherry¹⁰, Yuelong Shu¹¹, Derek Smith¹², Masato Tashiro⁸, Dayan Wang¹¹, Richard Webby¹⁰, Xiyan Xu⁴, Zhiping Ye¹³, Wenqing Zhang³; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013–2014

Collaborators, Affiliations

Collaborators

Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013–2014:
Ian G Barr, Colin Russell, Terry G Besselaar, Nancy J Cox, Rod S Daniels, Ruben Donis, Othmar G Engelhardt, Gary Grohmann, Shigeyuki Itamura, Anne Kelso, John McCauley, Takato Odagiri, Stacey Schultz-Cherry, Yuelong Shu, Derek Smith, Masato Tashiro, Dayan Wang, Richard Webby, Xiyan Xu, Zhiping Ye, Wenqing Zhang

Affiliations

¹ WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne, Australia. Electronic address: Ian.Barr@influenzacentre.org.
² University of Cambridge, UK.
³ WHO Global Influenza Programme (GIP), Geneva, Switzerland.
⁴ WHO Collaborating Centre for Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and Prevention, Atlanta, USA.
⁵ WHO Collaborating Centre for Reference and Research on Influenza, Medical Research Council - National Institute for Medical Research (NIMR), London, UK.
⁶ National Institute for Biological Standards and Control (NIBSC), Health Protection Agency (HPA), Potters Bar, UK.
⁷ Therapeutic Goods Administration (TGA), Canberra, Australia.
⁸ WHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases (NIID), Tokyo, Japan.
⁹ WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne, Australia.
¹⁰ St Jude Children's Research Hospital, Memphis, USA.
¹¹ WHO Collaborating Center for Reference and Research on Influenza, Chinese National Influenza Center (CNIC), Beijing, PR China.
¹² Centre for Pathogen Evolution and WHOCC for Modelling Evolution and Control of Emerging Infectious Diseases, University of Cambridge, UK and Fogarty International Centre, National Institutes of Health (NIH), USA.
¹³ Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Bethesda, MD, USA.

PMID: 24582632
DOI: 10.1016/j.vaccine.2014.02.014

Free article

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013

Ian G Barr et al. Vaccine. 2014.

Free article

. 2014 Aug 20;32(37):4713-25.

doi: 10.1016/j.vaccine.2014.02.014. Epub 2014 Feb 28.

Authors

Collaborators

Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013–2014:
Ian G Barr, Colin Russell, Terry G Besselaar, Nancy J Cox, Rod S Daniels, Ruben Donis, Othmar G Engelhardt, Gary Grohmann, Shigeyuki Itamura, Anne Kelso, John McCauley, Takato Odagiri, Stacey Schultz-Cherry, Yuelong Shu, Derek Smith, Masato Tashiro, Dayan Wang, Richard Webby, Xiyan Xu, Zhiping Ye, Wenqing Zhang

Affiliations

¹ WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne, Australia. Electronic address: Ian.Barr@influenzacentre.org.
² University of Cambridge, UK.
³ WHO Global Influenza Programme (GIP), Geneva, Switzerland.
⁴ WHO Collaborating Centre for Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and Prevention, Atlanta, USA.
⁵ WHO Collaborating Centre for Reference and Research on Influenza, Medical Research Council - National Institute for Medical Research (NIMR), London, UK.
⁶ National Institute for Biological Standards and Control (NIBSC), Health Protection Agency (HPA), Potters Bar, UK.
⁷ Therapeutic Goods Administration (TGA), Canberra, Australia.
⁸ WHO Collaborating Centre for Reference and Research on Influenza, National Institute of Infectious Diseases (NIID), Tokyo, Japan.
⁹ WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne, Australia.
¹⁰ St Jude Children's Research Hospital, Memphis, USA.
¹¹ WHO Collaborating Center for Reference and Research on Influenza, Chinese National Influenza Center (CNIC), Beijing, PR China.
¹² Centre for Pathogen Evolution and WHOCC for Modelling Evolution and Control of Emerging Infectious Diseases, University of Cambridge, UK and Fogarty International Centre, National Institutes of Health (NIH), USA.
¹³ Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Bethesda, MD, USA.

PMID: 24582632
DOI: 10.1016/j.vaccine.2014.02.014

Abstract

In February the World Health Organisation (WHO) recommends influenza viruses to be included in influenza vaccines for the forthcoming winter in the Northern Hemisphere. These recommendations are based on data collected by National Influenza Centres (NICs) through the WHO Global Influenza Surveillance and Response System (GISRS) and a more detailed analysis of representative and potential antigenically variant influenza viruses from the WHO Collaborating Centres for Influenza (WHO CCs) and Essential Regulatory Laboratories (ERLs). This article provides a detailed summary of the antigenic and genetic properties of viruses and additional background data used by WHO experts during development of the recommendations of the 2013-2014 Northern Hemisphere influenza vaccine composition.

Keywords: 2013–2014; Human; Influenza; Northern Hemisphere; Quadrivalent; Recommendation; Trivalent; Vaccine.

Published by Elsevier Ltd.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013

Collaborators

Affiliations

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013

Authors

Collaborators

Affiliations

Abstract

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical